Weekly issue 2026-W35 ·
The fibrocystin C-terminal domain inhibits Src/STAT3 signal induced cystogenesis of kidney epithelial cells.
Plain language
In recessive PKD, a broken fibrocystin protein lets kidney cells overreact through a Src/STAT3 signal, filling with fluid. Lab-grown kidney cells show the tail end of fibrocystin puts the brakes on — a possible future drug target. Cells in dishes, not patients.
Clinical note
In vitro ARPKD model (principal-like MDCK monolayers, 2D and 3D): FPC loss raises cAMP and secretion; wild-type FPC tail dampens Src–STAT3. Defines a druggable axis in principle — years from any therapy.
Question for your next visit
For my family member with recessive PKD, what would need to happen before a finding about fibrocystin could become a treatment tested in people?